PARIS (Reuters) – Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.
“We’re very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages,” said Thomas Triomphe, executive vice president for Sanofi Vaccines.
(Reporting by Sudip Kar-Gupta, Editing by Louise Heavens)
